Antoine Yver
At a Glance
Date of birth
January 31, 1958
Nationality
French, American, Swiss
First elected or appointed
May 2022
Term expires
General Meeting 2025
Education and Business Experience
Antoine Yver was in charge of the Development of Centessa Pharmaceuticals, Ltd. as Chairman in 2021 and 2022.
He began his oncology development career at Rhône Poulenc Rorer Inc. in 1990. In 1999, he joined the Aventis Group as Senior Director, Oncology Global Clinical Development. In 2005, he was appointed Senior Director of Oncology at Johnson & Johnson* and in 2006, Executive Director of Oncology at Schering-Plough.
From 2009 to 2016, he led global oncology development at AstraZeneca*, delivering TAGRISSO and LYNPARZA, including Senior Vice President, GMD Head of Oncology and Lead, China GMD (2013-2016). Subsequently, he was Executive Vice President, Global Head of Oncology Research and Development at Daiichi Sankyo* and developed ENHERTU.
Antoine Yver is a former intern in medicine at the Hôpitaux de Paris (AIHP) as well as a former assistant at the Hôpitaux de Paris in pediatrics and oncology and former head of clinic at the Universities. He is a Doctor of Medicine (MD) and Pediatrics from the University of Paris-Sud 11.
He also obtained a Master's degree in Immunology from the University of Paris.
Directorships & Appointments
Inside the Sanofi Group
Independent director
Chairman of the Scientific Committee
Member of the Strategy Committee
Outside the Sanofi Group
Spotlight Therapeutics: Board Member
D3 Bio: Independent Board Member
Meet the Sanofi Board of Directors
Frédéric Oudéa
Chairman of the Board of Directors
